Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 4
1998 4
1999 8
2000 1
2001 14
2002 11
2003 14
2004 14
2005 15
2006 21
2007 24
2008 28
2009 21
2010 25
2011 24
2012 14
2013 17
2014 19
2015 13
2016 10
2017 9
2018 12
2019 9
2020 7
2021 7
2022 6
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

307 results

Results by year

Filters applied: . Clear all
Page 1
International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.
Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. Staskin D, et al. J Urol. 2020 Aug;204(2):316-324. doi: 10.1097/JU.0000000000000807. Epub 2020 Feb 18. J Urol. 2020. PMID: 32068484 Clinical Trial.
MATERIALS AND METHODS: Adult patients with overactive bladder with 8.0 or more micturitions per day were randomized 5:5:4 to 75 mg vibegron, placebo or extended-release 4 mg extended-release tolterodine. Up to 25% of patients could have dry overactive bladder (less than 1. …
MATERIALS AND METHODS: Adult patients with overactive bladder with 8.0 or more micturitions per day were randomized 5:5:4 to 75 mg vibegron, …
Tolterodine--a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data.
Nilvebrant L, Hallén B, Larsson G. Nilvebrant L, et al. Life Sci. 1997;60(13-14):1129-36. doi: 10.1016/s0024-3205(97)00057-x. Life Sci. 1997. PMID: 9121357 Review.
A major active metabolite, (PNU-200577) the 5-hydroxymethyl derivative of tolterodine, has a similar pharmacological profile. Based on pharmacological and pharmacokinetic data, it has been concluded that this metabolite contributes significantly to the therapeutic effect o …
A major active metabolite, (PNU-200577) the 5-hydroxymethyl derivative of tolterodine, has a similar pharmacological profile. Based o …
Efficacy and Safety of Tolterodine and Pilocarpine in Patients with Overactive Bladder.
Ko KJ, Kim KH, Kim SW, Kim SO, Seo JT, Choo MS, Lee JZ, Oh SJ, Kim HG, Min KS, Kim JH, Lee KS. Ko KJ, et al. J Urol. 2019 Sep;202(3):564-573. doi: 10.1097/JU.0000000000000281. Epub 2019 Aug 8. J Urol. 2019. PMID: 31009289 Clinical Trial.
PURPOSE: We evaluated the efficacy and safety of a combination of 2 mg tolterodine and 9 mg pilocarpine, vs tolterodine monotherapy in patients with overactive bladder. ...Changes from baseline in the total xerostomia inventory score and the visual analogue scale fo …
PURPOSE: We evaluated the efficacy and safety of a combination of 2 mg tolterodine and 9 mg pilocarpine, vs tolterodine monoth …
Effect of combined use of tolterodine and continuous positive airway pressure vs continuous positive airway pressure only treatment on overactive bladder symptoms in women with moderate-to-severe obstructive sleep apnea syndrome: a randomized clinical trial.
Ertaş K, Yıldız H, Demir M, Aslan R, Eryılmaz R, Kırmızıtoprak Ş, Taken K. Ertaş K, et al. Int Urogynecol J. 2022 Jul;33(7):2031-2036. doi: 10.1007/s00192-022-05206-5. Epub 2022 Apr 21. Int Urogynecol J. 2022. PMID: 35445808 Clinical Trial.
This study aims to determine whether combined tolterodine and CPAP therapies are more effective for patients with OSAS than CPAP treatment only. ...CONCLUSIONS: In this study, combined use of tolterodine with CPAP provides beneficial effects to CPAP treatment only r …
This study aims to determine whether combined tolterodine and CPAP therapies are more effective for patients with OSAS than CPAP trea …
A comparison of the efficacy and tolerability of treating primary nocturnal enuresis with Solifenacin Plus Desmopressin, Tolterodine Plus Desmopressin, and Desmopressin alone: a randomized controlled clinical trial.
Ghanavati PM, Khazaeli D, Amjadzadeh M. Ghanavati PM, et al. Int Braz J Urol. 2021 Jan-Feb;47(1):73-81. doi: 10.1590/S1677-5538.IBJU.2019.0448. Int Braz J Urol. 2021. PMID: 32840337 Free PMC article. Clinical Trial.
OBJECTIVES: In this study, we compared therapeutic efficacy and tolerability of treating primary nocturnal enuresis (PNE) with solifenacin plus desmopressin, tolterodine plus desmopressin, and desmopressin alone. Because we don't have enough information about this comparis …
OBJECTIVES: In this study, we compared therapeutic efficacy and tolerability of treating primary nocturnal enuresis (PNE) with solifenacin p …
Comparing the Efficacy of Tolterodine and Gabapentin Versus Placebo in Catheter Related Bladder Discomfort After Percutaneous Nephrolithotomy: A Randomized Clinical Trial.
Maghsoudi R, Farhadi-Niaki S, Etemadian M, Kashi AH, Shadpour P, Shirani A, Samadinezhad-Khoshbaf-Sorkhabi R, Tabatabaei M. Maghsoudi R, et al. J Endourol. 2018 Feb;32(2):168-174. doi: 10.1089/end.2017.0563. Epub 2018 Jan 26. J Endourol. 2018. PMID: 29278929 Clinical Trial.
PURPOSE: The purpose of this study was to compare the efficacy of tolterodine and gabapentin vs placebo in catheter related bladder discomfort (CRBD) following percutaneous nephrolithotomy (PCNL). ...CONCLUSIONS: Preoperative administration of oral tolterodine or ga …
PURPOSE: The purpose of this study was to compare the efficacy of tolterodine and gabapentin vs placebo in catheter related bladder d …
Clinical safety, tolerability and efficacy of combination tolterodine/pilocarpine in patients with overactive bladder.
Dmochowski RR, Staskin DR, Duchin K, Paborji M, Tremblay TM. Dmochowski RR, et al. Int J Clin Pract. 2014 Aug;68(8):986-94. doi: 10.1111/ijcp.12409. Epub 2014 Mar 25. Int J Clin Pract. 2014. PMID: 24666884 Clinical Trial.
Tolterodine/pilocarpine (2/9) was associated with consistently lower Visual Analogue Scale (VAS) scores for all dry mouth parameters compared with tolterodine alone. Salivary flow over a 3 h period remained fairly constant after tolterodine/pilocarpine (2/9) …
Tolterodine/pilocarpine (2/9) was associated with consistently lower Visual Analogue Scale (VAS) scores for all dry mouth parameters …
Effects of terazosin and tolterodine on ureteral stent related symptoms: a double-blind placebo-controlled randomized clinical trial.
Tehranchi A, Rezaei Y, Khalkhali H, Rezaei M. Tehranchi A, et al. Int Braz J Urol. 2013 Nov-Dec;39(6):832-40. doi: 10.1590/S1677-5538.IBJU.2013.06.09. Int Braz J Urol. 2013. PMID: 24456787 Free article. Clinical Trial.
OBJECTIVE: To evaluate the effects of terazosin and tolterodine on ureteral stent discomfort. MATERIALS AND METHODS: Of 163 patients assessed for eligibility, 104 patients were randomly assigned to receive placebo, 2 mg of terazosin twice daily, 2 mg of tolterodine …
OBJECTIVE: To evaluate the effects of terazosin and tolterodine on ureteral stent discomfort. MATERIALS AND METHODS: Of 163 patients …
Comparison of the Efficacy of Tolterodine versus Oxybutynin in the Treatment of Children with Desmopressin-Resistant Enuresis: A Randomized Controlled Clinical Trial.
Ezodin N, Sarouei M, Khademlo M, Milani SH, Yousefi S, Mohammadjafari H. Ezodin N, et al. Ethiop J Health Sci. 2023 Jul;33(4):611-620. doi: 10.4314/ejhs.v33i4.7. Ethiop J Health Sci. 2023. PMID: 38784212 Free PMC article. Clinical Trial.
This study evaluated the effectiveness of Tolterodine and Oxybutynin in children presenting with primary desmopressin-resistant enuresis. ...However, no benefit was observed in using either Oxybutynin or Tolterodine in the treatment of Desmopressin-resistant enuresi …
This study evaluated the effectiveness of Tolterodine and Oxybutynin in children presenting with primary desmopressin-resistant enure …
Efficacy and Safety of Medium-to-long-term Use of Tolterodine Extended Release with or without Tamsulosin in Patients with Benign Prostate Hyperplasia and Larger Prostate Size: A Double-blind, Placebo-controlled, Randomized Clinical Trial.
Cai JL, Zhou Z, Yang Y, Yan YF, Jing S, Na YQ. Cai JL, et al. Chin Med J (Engl). 2016 Dec 20;129(24):2899-2906. doi: 10.4103/0366-6999.195461. Chin Med J (Engl). 2016. PMID: 27958220 Free PMC article. Clinical Trial.
The patients were randomized into four groups (n = 38 in each) to receive tolterodine ER placebo plus tamsulosin placebo, 0.2 mg tamsulosin plus tolterodine ER placebo, 4 mg tolterodine ER plus tamsulosin placebo, or tolterodine ER plus tamsulosin once …
The patients were randomized into four groups (n = 38 in each) to receive tolterodine ER placebo plus tamsulosin placebo, 0.2 mg tams …
307 results